|
| 37767768 | Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. | Blood Cancer Discov | 2024 |
| 37934799 | ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. | Blood Cancer Discov | 2024 |
| 37486974 | Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. | | 2023 |
| 37608773 | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. | Haematologica | 2023 |
| 37847871 | Glücksklee, the Quad, and High-Risk Myeloma. | | 2023 |
| 38024593 | Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. | | 2023 |
| 37745615 | Majority of human circulating plasmablasts stop blasting: A probable misnomer. | | 2023 |
| 37662390 | Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. | | 2023 |
| 37646702 | Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2023 |
| 37808071 | Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. | | 2023 |
| 37790523 | Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. | | 2023 |
| 37622738 | Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. | Cancer | 2023 |
| 36511813 | Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. | Blood Cancer Discov | 2023 |
| 37145495 | Novel approaches to the treatment of multiple myeloma. | | 2023 |
| 36711623 | Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses. | | 2023 |
| 36638355 | Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma. | | 2023 |
| 36631458 | A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. | | 2023 |
| 36566137 | Disparities in multiple myeloma among African Americans. | | 2023 |
| 36627265 | Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. | | 2023 |
| 36804376 | Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. | | 2023 |
| 37355988 | Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. | | 2023 |
| 37528088 | Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. | Blood Cancer J | 2023 |
| 37526080 | Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. | J Clin Invest | 2023 |
| 37516547 | Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. | | 2023 |
| 35306217 | ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. | Transplantation and Cellular Therapy | 2022 |
| 35653112 | Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. | Blood Cancer Discov | 2022 |
| 36170375 | Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. | Sci Adv | 2022 |
| 35511673 | β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. | Haematologica | 2022 |
| 36209764 | Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. | Lancet Haematology,The | 2022 |
| 35941288 | When an embarrassment of riches isn't enough. | Nature Reviews Clinical Oncology | 2022 |
| 35550060 | Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. | Lancet Haematology,The | 2022 |
| 36064707 | Smoldering multiple myeloma current treatment algorithms. | Blood Cancer Journal | 2022 |
| 35927247 | Venetoclax ex vivo functional profiling predicts improved progression-free survival. | Blood Cancer J | 2022 |
| 35660812 | Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. | N Engl J Med | 2022 |
| 34626863 | Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. | Transplantation and Cellular Therapy | 2022 |
| 35259002 | Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. | Journal of Clinical Oncology | 2022 |
| 35148975 | Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 35114153 | Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. | Lancet Haematology,The | 2022 |
| 35114152 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. | Lancet Haematol | 2022 |
| 35122287 | Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. | Pharmacotherapy | 2022 |
| 34529955 | Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. | Lancet Haematol | 2021 |
| 35846096 | Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. | | 2021 |
| 33485428 | Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2021 |
| 34289383 | Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. | Mol Cell | 2021 |
| 33739965 | Antibody treatment in multiple myeloma. | Clinical Advances in Hematology and Oncology | 2021 |
| 34111942 | What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. | Journal of Clinical Oncology | 2021 |
| 33626253 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. | New England Journal of Medicine | 2021 |
| 34274290 | Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| 33731366 | Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. | Clin Cancer Res | 2021 |
| 33662288 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. | Lancet Oncol | 2021 |